Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Takeda Buys Rare Cancer Drug Developer in Estimated $5.2B Deal

By Ryan Bushey | January 10, 2017

Japanese drugmaker Takeda acquired Boston-based Ariad Pharmaceuticals, a biotech company specializing in cancer drugs, in a deal worth up to $5.2 billion.

This agreement strengthens Takeda’s oncology offerings by giving it ownership of two cancer treatments, Iclusig and Brigatinib.

Iclusing is approved as a last-resort treatment chronic myeloid leukemia and for acute lymphoblastic leukemia patients with a rare genetic abnormality, according to Xconomy.  Brigatinib is intended for non-small cell lung cancer, but an approval decision from the Food and Drug Administration is expected at the end of April.

Analysts predict Iclusing could become a $500 million plus-product at its peak while both medications could bring in $2 billion in U.S. sales in the next decade, wrote FiercePharma.

“This is a very exciting time for Takeda as we will broaden our hematology portfolio and transform our global solid tumor franchise through the addition of two innovative targeted therapies. Opportunities to acquire such high-quality, complementary targeted therapies do not come often, and we are very excited about the potential for this transaction to benefit patients, our shareholders and other stakeholders,” said Takeda’s president and CEO Christophe Weber in a statement.

Essentially, this acquisition diversifies Takeda’s cancer portfolio as its top-selling blood cancer drug Velcade is predicted to face generic competition. Ariad wins with this arrangement because Takeda has a history of successful global oncology drug launches too.

This deal is expected to close by the end of next month.


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE